NCT04119921View on ClinicalTrials.gov

Short-term Additive Effect of Topical Ketorolac on the Management of Diabetic Macular Edema With Intravitreal Bevacizumab

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

June 1, 2018

Study Completion Date

June 20, 2020

Conditions
DME
Interventions
DRUG

prescription topical ketorolac in group 1

topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.

DRUG

prescription artificial tear in group 2

artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.

DRUG

prescription topical ketorolac in group 2

artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.

DRUG

prescription artificial tear in group1

topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.

Trial Locations (1)

Unknown

Ophthalmic Research Center, Tehran

All Listed Sponsors
lead

Shahid Beheshti University of Medical Sciences

OTHER

NCT04119921 - Short-term Additive Effect of Topical Ketorolac on the Management of Diabetic Macular Edema With Intravitreal Bevacizumab | Biotech Hunter | Biotech Hunter